Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.65 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | VHL | P40337 | 1/20 | 0.38 |
| ▸ | ELOC | Q15369 | 1/20 | 0.38 |
| ▸ | ELOB | Q15370 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685103 | 0.86 | ESR1 (0.74) | ESR1THRATHRBTSHRESR2 | |
| SCHEMBL73405 | 0.79 | ESR1 (1.00) | ESR1THRATHRBTSHRESR2 | |
| SCHEMBL15927653 | 0.79 | ESR1 (0.46) | ESR1THRATHRBPPARGPPARA | |
| SCHEMBL31166664 | 0.78 | ESR1 (0.41) | ESR1THRATHRBPPARGPPARA | |
| SCHEMBL21100336 | 0.78 | ESR1 (0.64) | ESR1THRATHRBESR2SLC6A2 | |
| SCHEMBL28092549 | 0.77 | ESR1 (0.95) | ESR1THRATHRBTSHRESR2 | |
| SCHEMBL20781809 | 0.77 | PRKCI (0.54) | ESR1KIF11 | |
| SCHEMBL10294037 | 0.77 | ENPP2 (0.45) | ESR1TSHRPRSS1PRSS2PRSS3 | |
| SCHEMBL26569953 | 0.77 | ESR1 (0.56) | ESR1THRATHRBPPARAEPHX2 | |
| SCHEMBL41775 | 0.76 | TSHR (0.67) | ESR1PPARGPPARATSHRESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| US-20230303539-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-11674139-B2 | Oligonucleotides for treating expanded repeat diseases | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220193080-A1 | ALLOSTERIC AGONISTS AND POSITIVE ALLOSTERIC MODULATORS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR | UNIVERSITY OF THE SCIENCES (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220018826-A1 | COLORIMETRIC PLASMONIC NANOSENSOR FOR DOSIMETRY OF THERAPEUTIC LEVELS OF IONIZING RADIATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-01-20 | — | — | US | disclosed |
| US-11219625-B2 | Inhibitors of N-linked glycosylation and methods using same | YALE UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| US-6706910-B2 | BY TRANSESTERIFICATION OF A CYCLOPROPANECARBOXYLATE AND A MONOHYDROXY COMPOUND IN THE PRESENCE OF A LITHIUM ALKOXIDE OR LITHIUM ARYLOXIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-03-16 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-20020151741-A1 | Process for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-17 | — | — | US | disclosed |
| US-6441220-B1 | ESTERIFICATION WITH ALCOHOL IN PRESENCE OF BASIC CATALYSTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-27 | — | — | US | disclosed |
| EP-1227077-A2 | Process for producing cyclopropanecarboxylates | Sumitomo Chemical Co.,Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-1203760-A1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-08 | — | — | EP | disclosed |
| US-20020052525-A1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-02 | — | — | US | disclosed |
| EP-1061065-A2 | Methods for producing cyclopropane carboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-20 | — | — | EP | disclosed |
| US-6090961-A | Method for producing titanium complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-07-18 | — | — | US | disclosed |
| EP-0970964-A2 | Method for producing titanium complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151741-A1 | Process for producing cyclopropanecarboxylates | CYC1, CYP21A2, CYP2A6 | ESR1 4753/4885THRA 3923/4885THRB 4200/4885 |
| US-20230303539-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | TNF, NFATC1, IL2 | ESR1 3115/4885THRA 1908/4885THRB 2100/4885 |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | HTT, UPF1, TARDBP | ESR1 4046/4885THRA 2209/4885THRB 2296/4885 |
| US-11746116-B2 | Antibiotic resistance breakers | ABCC1, ARL1, AKR1C3 | ESR1 446/4885THRA 764/4885THRB 1390/4885 |
| US-20020052525-A1 | Method for producing cyclopropanecarboxylates | CYP8B1, SRD5A2, CYP21A2 | ESR1 4123/4885THRA 2421/4885THRB 2193/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | ESR1 2025/4885THRA 3891/4885THRB 4264/4885 |
| US-11219625-B2 | Inhibitors of N-linked glycosylation and methods using same | ENGASE, FUT5, B3GNT2 | ESR1 4709/4885THRA 4512/4885THRB 4190/4885 |
| US-11674139-B2 | Oligonucleotides for treating expanded repeat diseases | HTT, UPF1, TARDBP | ESR1 4046/4885THRA 2209/4885THRB 2296/4885 |
| US-20220193080-A1 | ALLOSTERIC AGONISTS AND POSITIVE ALLOSTERIC MODULATORS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR | GLP1R, GPR119, GIPR | ESR1 286/4885THRA 47/4885THRB 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.